Corticosteroids Market Size & Growth Forecast 2027–2036, By Segments (Product, Distribution Channel, Route of Administration, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Corticosteroids Market size was around USD 6.11 billion in 2026 and is slated to grow at a 5.04% CAGR from 2027 to 2036, crossing USD 9.99 billion by 2036. The industry revenue for 2027 is calculated at USD 6.4 billion.
Get more details on this report
Request Free Sample ReportCorticosteroids Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through established prescribing patterns, specialist access, mature healthcare systems, and consistent use of therapies across inflammatory and autoimmune conditions.
- Asia Pacific is projected to grow at a 6.33% CAGR, supported by improving healthcare access, broader therapy availability, and rising treatment uptake.
Segment Momentum
- Hospital Pharmacies lead the market because corticosteroid therapies are frequently initiated, adjusted, and monitored in inpatient and specialist care settings where physician oversight is essential.
- Online Pharmacies are the fastest-growing channel, supported by growing demand for convenient prescription fulfillment, home delivery, and easier refill access for ongoing corticosteroid therapies.
Market Expansion Drivers
- Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management.
- Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders.
- Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes.
Leading Market Participants
- Prominent players in the corticosteroids market include Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca PLC (U.K.), GSK plc (U.K.), Merck KGaA (Germany), Abbott Laboratories (U.S.), Cipla Limited (India), Eli Lilly and Company (U.S.), Sanofi S.A. (France), ReveraGen BioPharma, Inc. (U.S.).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.11 billion
- 2027 Estimated Market Size: USD 6.4 billion.
- Projected Market Size: USD 9.99 billion by 2036
- Growth Forecast: 5.04% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Glucocorticoids (Product) | Hospital Pharmacies (Distribution Channel) | Inhaled (Route of Administration) | Respiratory Disorders (Application)
- Emerging Opportunity Segment: Mineralocorticoids (Product) | Online Pharmacies (Distribution Channel) | Injectable (Route of Administration) | Autoimmune Diseases (Application)
Market Growth Drivers and Industry Trends
Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management
The increasing burden of cancer is contributing to demand for supportive therapies that help manage inflammation and treatment-related symptoms, supporting the corticosteroids market across oncology care settings. Corticosteroids may be used in selected cancer treatment pathways to reduce inflammation, control certain symptoms, and help manage adverse effects associated with cancer and its treatment. Their clinical versatility allows healthcare professionals to incorporate these medicines into supportive care according to individual patient requirements. As oncology services expand and more patients require comprehensive management throughout diagnosis and treatment, corticosteroids remain relevant across hospitals, specialist clinics, and other healthcare settings.
Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders
Higher healthcare spending and improvements in medical access are enabling more patients to receive treatment for chronic inflammatory, autoimmune, and respiratory conditions, which will drive the corticosteroids market. Corticosteroids are used across several therapeutic areas because of their ability to suppress inflammation and modulate immune responses, making them relevant to conditions that require management of persistent or severe inflammatory symptoms. Greater availability of diagnostic services can also support identification and treatment of patients who previously had limited access to specialized care. As healthcare systems strengthen their capacity to manage chronic disorders, corticosteroid therapies remain part of treatment strategies across multiple clinical specialties.
Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes
Corticosteroids play an important role in the management of selected severe respiratory conditions where controlling airway or systemic inflammation is clinically necessary, strengthening the corticosteroids market in hospital settings. Critical respiratory care environments require rapid access to established therapies that can be incorporated into treatment protocols according to disease severity and patient condition. The increasing focus on timely management of respiratory deterioration is supporting the use of corticosteroids in appropriate clinical situations, particularly where inflammatory responses contribute to breathing complications. Their availability across hospital pharmacies and acute-care facilities supports treatment delivery during intensive respiratory management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management | 2.10% | High | Asia Pacific, North America | High | Near Term |
| Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders | 1.80% | Moderate | Europe, Asia Pacific | High | Mid Term |
| Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes | 1.50% | High | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The North America corticosteroids market held the largest share in 2026, supported by advanced healthcare infrastructure, broad access to prescription medicines, and established treatment protocols across inflammatory, autoimmune, respiratory, dermatological, and other conditions. The region's mature pharmaceutical distribution system facilitates availability of corticosteroid formulations across hospitals, clinics, pharmacies, and outpatient settings. Continued demand for effective anti-inflammatory and immunosuppressive therapies, combined with ongoing clinical research and improvements in drug delivery approaches, supports market activity. Furthermore, established regulatory and healthcare frameworks encourage standardized prescribing and monitoring practices, while increasing attention to chronic disease management sustains demand across multiple therapeutic applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by improving healthcare infrastructure, rising medical expenditure, and expanding access to pharmaceutical treatments. Growing diagnosis and management of inflammatory, respiratory, dermatological, and autoimmune conditions are broadening the patient base requiring corticosteroid therapies. Increased availability of healthcare services and pharmaceutical products is also improving treatment access across developing markets. In addition, expanding domestic pharmaceutical manufacturing capabilities and greater awareness of disease management are supporting wider utilization of corticosteroid formulations, while healthcare modernization initiatives continue to strengthen the region's capacity to deliver essential therapies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Guideline-Based PrescribingGermany emphasizes corticosteroid use aligned with established clinical guidelines and individualized patient management. Healthcare institutions in Germany focus on optimizing treatment protocols while encouraging careful monitoring to improve therapeutic outcomes and minimize adverse effects.
France 🇫🇷
Responsible Therapeutic UseFrance promotes corticosteroid prescribing practices that balance clinical benefits with long-term patient safety. Healthcare professionals in France increasingly emphasize evidence-based treatment selection, regular follow-up, and appropriate therapy adjustments across multiple therapeutic indications.
Italy 🇮🇹
Hospital and Outpatient BalanceItaly maintains broad corticosteroid utilization across hospital care, specialty clinics, and outpatient treatment settings. Clinicians in Italy continue emphasizing individualized treatment plans, careful dose management, and appropriate formulation selection to support effective inflammatory disease control.
Japan 🇯🇵
Specialized Therapy OptimizationJapan prioritizes corticosteroid formulations that support specialized treatment across inflammatory and immune-related conditions. Pharmaceutical companies in Japan continue improving formulation quality and delivery options to enhance patient adherence and clinical effectiveness.
South Korea 🇰🇷
Advanced Treatment IntegrationSouth Korea continues incorporating corticosteroids into multidisciplinary treatment pathways for chronic inflammatory disorders. Healthcare providers in South Korea increasingly favor optimized formulations and patient monitoring approaches that support effective disease management across clinical settings.
United States 🇺🇸
Diverse Clinical ApplicationsThe U.S. corticosteroids market is supported by broad therapeutic use across respiratory, dermatology, rheumatology, and autoimmune disease management. Healthcare providers in the U.S. increasingly balance treatment effectiveness with appropriate dosing strategies and long-term safety considerations.
Segment Leadership and Growth Trends
Corticosteroids Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Glucocorticoids (Largest Segment) vs Mineralocorticoids (Fastest-Growing Segment)
Glucocorticoids held the largest position in the corticosteroids market in 2026, reflecting their broad therapeutic application across inflammatory, allergic, autoimmune, and other medical conditions. Their established role in managing conditions requiring anti-inflammatory and immunosuppressive effects supports consistent clinical utilization. Continued demand for effective treatment options across multiple therapeutic settings reinforces the segment's strong market position.
Mineralocorticoids are experiencing the fastest growth as demand increases for therapies addressing conditions associated with electrolyte balance and adrenal hormone deficiencies. Greater attention to appropriate hormone replacement and management of related disorders is supporting utilization of mineralocorticoid therapies. Increasing clinical recognition of targeted treatment requirements is contributing to the segment's expanding role within the corticosteroids landscape.
Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)
Hospital pharmacies accounted for the largest share in 2026 in the corticosteroids market, supported by their direct integration with clinical care and their role in supplying medications to hospitalized and outpatient patients. These pharmacies facilitate timely access to prescribed corticosteroid therapies while supporting medication management and coordination with healthcare professionals. Their proximity to treatment settings and established dispensing infrastructure continues to underpin their leading position.
Online pharmacies are growing at the fastest pace as consumers increasingly seek convenient and accessible channels for obtaining prescribed and over-the-counter healthcare products. Digital ordering, home delivery, and streamlined access to medication information are improving convenience for patients managing ongoing treatment needs. The broader shift toward digitally enabled healthcare services is encouraging greater acceptance of online pharmaceutical distribution.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Glucocorticoids, Mineralocorticoids | Glucocorticoids | Mineralocorticoids |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Hospital Pharmacies | Online Pharmacies |
| Route of Administration | Oral, Topical, Inhaled, Injectable | Inhaled | Injectable |
| Application | Autoimmune Diseases, Skin Disorders, Respiratory Disorders, Allergic Conditions, Others | Respiratory Disorders | Autoimmune Diseases |
Competitive Landscape and Market Positioning
Leading companies in the corticosteroids market:
1. Pfizer Inc. (U.S.)
2. Novartis AG (Switzerland)
3. AstraZeneca PLC (U.K.)
4. GSK plc (U.K.)
5. Merck KGaA (Germany)
6. Abbott Laboratories (U.S.)
7. Cipla Limited (India)
8. Eli Lilly and Company (U.S.)
9. Sanofi S.A. (France)
10. ReveraGen BioPharma Inc. (U.S.)
The corticosteroids market is progressing through continuous improvements in drug delivery systems, formulation technologies, and targeted therapeutic applications across inflammatory and respiratory conditions. Pharmaceutical companies are focusing on minimizing side effects while enhancing treatment effectiveness and patient adherence. Increased research into advanced corticosteroid therapies is also contributing to innovation within the corticosteroids market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (U.S.) | |||||||
| Novartis AG (Switzerland) | |||||||
| AstraZeneca PLC (U.K.) | |||||||
| GSK plc (U.K.) | |||||||
| Merck KGaA (Germany) | |||||||
| Abbott Laboratories (U.S.) | |||||||
| Cipla Limited (India) | |||||||
| Eli Lilly and Company (U.S.) | |||||||
| Sanofi S.A. (France) | |||||||
| ReveraGen BioPharma Inc. (U.S.). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GSK | Feb-26 | GSK received European Commission approval for Exdensur, a twice-yearly treatment for severe asthma and chronic rhinosinusitis with nasal polyps. This authorization expands the company’s respiratory portfolio within the European market, following similar regulatory successes in the United States and Japan, and positions the biologic as a significant alternative to traditional corticosteroid-dependent treatment regimens. |
| GSK | Dec-25 | The European Medicines Agency’s CHMP issued positive endorsements for GSK’s long-acting asthma therapy, depemokimab. This regulatory milestone supports the company’s strategic objective to capture market share in respiratory and inflammation care by transitioning patient treatment pathways toward high-value biologic therapies that offer clinical alternatives to conventional corticosteroid management. |
| Amgen, AstraZeneca | Oct-25 | Amgen and AstraZeneca secured FDA approval for Tezspire in the treatment of chronic rhinosinusitis with nasal polyps. Following positive Phase III data demonstrating significant reductions in polyp severity, this label expansion broadens the biologic’s competitive footprint across inflammatory respiratory conditions, directly impacting the clinical utility of standard corticosteroid therapies. |
| Eli Lilly | Jul-25 | Eli Lilly secured reimbursement-backed access for Ebglyss (lebrikizumab) in South Korea. This strategic move strengthens the company's position in the atopic dermatitis biologics segment, providing clinicians with a targeted alternative to corticosteroid-based therapies and potentially altering treatment patterns within the regional dermatology market. |
| LEO Pharma | Oct-24 | LEO Pharma launched Anzupgo in Germany, representing the first approved topical treatment specifically indicated for chronic hand eczema. This launch marks a strategic expansion in the dermatology therapeutics market, aiming to capture volume from conventional corticosteroid treatments by offering a specialized therapeutic alternative for patients with localized inflammatory skin conditions. |
| Sanofi, Regeneron | Sep-24 | Sanofi and Regeneron initiated plans to seek regulatory approval for Dupixent in treating bullous pemphigoid following successful Phase III trials. This development signifies a major effort to expand the biologic’s application into skin disorders historically reliant on systemic corticosteroid therapy, threatening to disrupt traditional clinical approaches for these inflammatory conditions. |
| LEO Pharma | May-24 | LEO Pharma progressed its topical JAK inhibitor strategy with the development of delgocitinib cream. The product is positioned to compete directly in the atopic dermatitis market, diversifying therapeutic options and providing a non-corticosteroid alternative for patients requiring long-term topical inflammation management. |
| Ekuinas | Apr-24 | Ekuinas acquired an 80% stake in pharmaceutical ingredients producer Symbiotica. This acquisition represents a strategic investment in the healthcare and drug ingredient manufacturing value chain, enhancing regional production capabilities and supply chain resilience for pharmaceutical participants operating within the broader medicine market, including those producing steroid-based therapeutics. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Corticosteroids Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Severity | Mild, Moderate, Severe |
| Patient Age Group | Pediatric, Adult, Geriatric |
| Brand Type | Branded Drugs, Generic Drugs |
Corticosteroids Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Treatment Pathway and Prescribing Pattern Assessment |
|
| Generic Competition and Lifecycle Management Analysis |
|
| Steroid-Sparing Therapy Impact Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much is the corticosteroids market worth?
How is the corticosteroids industry expected to grow over the next 10 years?
Why is oncology care becoming an important demand driver for the corticosteroids market?
How is expanding healthcare expenditure supporting growth in the corticosteroids market?
Why do hospital pharmacies account for the largest share of the corticosteroids market?
How are online pharmacies gaining traction in the corticosteroids market?
Why does North America hold the largest share of the corticosteroids market?
How is Asia Pacific accelerating corticosteroids market growth?
What are the key competitors in the corticosteroids landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization